Trial
NCT01047319
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Relapsing Multiple Sclerosis
Intervention
Laquinimod
Why stopped
Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-09